The role of the Administrative core is to coordinate and integrate the multiple components of the ECOG-ACRIN Statistics and Data Management Center (SDMC) and to provide scientific, administrative, and fiscal oversight of SDMC activities. It is also responsible for coordinating collaborations with other NCTN Groups and other research organizations, for coordinating the participation of the SDMC in the collective management of the NCTN, and for ensuring timely provision of data and other resources generated from ECOG-ACRIN projects to the broader scientific community. The SDMC consists of the Biostatistics Center, with personnel at the Dana-Farber Cancer Institute (SDMC-DFCI) and Brown University (SDMC-Brown), and the Data Management Center, with personnel at the ECOG-ACRIN Medical Research Foundation (SDMC-EAMRF) and at the American College of Radiology (SDMC-ACR). The Group Statisticians, Dr. Robert Gray at DFCI and Dr. Constantine Gatsonis at Brown are responsible for all aspects of the SDMC operations. SDMC-DFCI and SDMC- EAMRF are responsible for therapeutic studies, under the leadership of Dr. Gray, and SDMC-Brown and SDMC-ACR are responsible for diagnostic and advanced imaging studies, under the leadership of Dr. Gatsonis. The SDMC components use a common set of Standard Operating Procedures. There are well-established procedures to facilitate communication and coordination among the components and between the SDMC and other ECOG-ACRIN components. The SDMC participates fully in the collective management of the NCTN and has numerous collaborations with other research entities. The SDMC has provided data from ECOG-ACRIN studies to numerous researchers. Going forward, most data sharing will be occurring through the NCTN/NCORP Data Archive, and the SDMC is fully committed to timely submission of data sets from ECOG-ACRIN publications to the Archive. The SDMC is also contributing image libraries to The Cancer Imaging Archive.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180794-06
Application #
9627513
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-04
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ratai, Eva-Maria; Zhang, Zheng; Fink, James et al. (2018) ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One 13:e0198548
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087

Showing the most recent 10 out of 187 publications